Download MendeleyDiscovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
Bregman, H., Chakka, N., Guzman-Perez, A., Gunaydin, H., Gu, Y., Huang, X., Berry, V., Liu, J., Teffera, Y., Huang, L., Egge, B., Mullady, E.L., Schneider, S., Andrews, P.S., Mishra, A., Newcomb, J., Serafino, R., Strathdee, C.A., Turci, S.M., Wilson, C., Dimauro, E.F.(2013) J Med Chem 56: 4320-4342
- PubMed: 23701517
- DOI: https://doi.org/10.1021/jm4000038
- Primary Citation of Related Structures:
4K4E, 4K4F - PubMed Abstract:
Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PARP) whose activity suppresses cellular axin protein levels and elevates β-catenin concentrations, resulting in increased oncogene expression. The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of β-catenin-mediated transcription and inhibit tumorigenesis. Compound 1 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinetic properties. Herein, we describe the utilization of structure-based design and molecular modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic properties (39, 40).
Organizational Affiliation:
Department of Chemistry Research and Discovery, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, USA. hbregman@amgen.com
